News Analysis Sinovac Biotech is the largest producer of the COVID-19 vaccine in China. Despite concerns over the efficacy of the Sinovac vaccine, the biopharmaceutical company’s subsidiary made a net profit of $1.67 billion in the first quarter of this year alone. While Sinovac is generating large profits, it’s noteworthy that some of its investors have strong political ties to the Chinese Communist Party and they also manage a few U.S. pension funds through a company called CDH Investments. As of June 1, Sinovac Life Sciences Co., Ltd. (Sinovac Life), a subsidiary of Sinovac Biotech, had supplied 600 million doses of the vaccine to nearly 40 countries and regions. According to a May 12 report on Beijing’s mouthpiece People’s Daily, Sinovac Life has completed the third phase of the production of its CoronaVac and its annual vaccine production capacity could reach 2 billion doses. Sinovac Life Earns $1.67 Billion in 3 Months On …